Nanocarriers for Biologicals Delivery to Cardiovascular System
- By Fahima Dilnawaz1
-
View Affiliations Hide Affiliations1 Laboratory of Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, Odisha, India
- Source: Nanomedicinal Approaches Towards Cardiovascular Disease , pp 61-69
- Publication Date: July 2021
- Language: English
Preview this chapter:
Nanocarriers for Biologicals Delivery to Cardiovascular System, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789814998215/chapter-7-1.gif
As cardiovascular diseases remain the leading cause of mortality worldwide, a large number of clinical trials are under development, investigating the safety and efficacy of RNA therapeutics in clinical conditions. Nanomedicine based drug delivery systems are currently the new avenue for the treatment of CVDs, providing great advantages to the treatment regime of CVDs. Currently, antisense therapy DNA- and RNA-based and microRNAs are widely applied therapeutic strategies to regulate gene expression and its effect on CVDs. In this review, different biological-based targeting therapies for cardiovascular diseases and their outcomes are discussed.
Hardbound ISBN:
9789814998222
Ebook ISBN:
9789814998215
-
From This Site
/content/books/9789814998215.chapter-7dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
/content/books/9789814998215.chapter-7
dcterms_subject,pub_keyword
-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData
10
5
Chapter
content/books/9789814998215
Book
false
en
